Provectus Biopharmaceuticals, Inc. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-100.0% -$14K
$0
Cost of Revenue
—
Gross Profit
—
R&D↓-55.9% -$340K
$268K
D&A↓-0.2% -$1
$465
Operating Income↓-33.5% -$320K
$-1M
EBITDA↓-0.2% -$1
$465
Interest Expense
—
Interest Income
—
Net Income↓-29.3% -$297K
$-1M
Gross Margin
—
Operating Margin↓-2821.1pts
-3132.8%
Net Margin↓-2890.0pts
-3222.1%
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.0pts
-5.1%
Operating Lease Cost
—
Revenue YoY Variation↓-11.8pts
-100.0%
Income YoY Variation↑+0.4pts
-33.5%
Revenue QoQ Variation↓-43.0pts
-100.0%
Income QoQ Variation↑+49.4pts
29.2%